Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with renal vasculitis
Rituximab showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events · adults with renal vasculitis
Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).
1 finding from 1 review
Serious adverse events · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).
1 finding from 1 review
Serious adverse events* · adults with renal vasculitis for maintenance therapy
Leflunomide showed no clear difference in serious adverse events* compared with methotrexate (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
Urtoxazumab (3.0 mg/kg) may leads to lower adverse events ‐ serious compared with placebo (low certainty).
1 finding from 1 review
Adverse events ‐ serious · paediatric patients with diarrhoea due to Shiga toxin‐producing E. coli
1 finding from 1 review
Adverse events: serious infections · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: serious infections compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: treatment failure (non response, serious infection, persistently elevated creatinine) at 6 months · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor probably leads to lower adverse events: treatment failure at 6 months (non response, serious… compared with IV cyclophosphamide (moderate certainty).
1 finding from 1 review